Recruiting
Phase 1

PF-07328948

Sponsor:

Pfizer

Code:

NCT07315360

Conditions

Renal Impairment

Healthy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

PF-07328948

Study Details

Brief summary:

The purpose of this study is to learn how the study medicine PF-07328948 is processed by the body and how safe and tolerable it is in adults with different levels of kidney function.

The study will include participants who:

  • Are aged 18 to 80 years.
  • Either have normal kidney function or long-term reduced kidney function (moderate or severe).
  • Have a BMI (body mass index) of 17.5 to 40 kilogram per meter squared, inclusive, and a total body weight of more than or equal to 45 kilograms or 99 pounds.

All participants will receive a single dose of PF-07328948 as a tablet taken by mouth. Participants will stay at a clinical research unit for about 6 days to receive the study medicine and undergo safety checks. Total participation lasts up to 64 days, including screening, inpatient stay, and a follow-up call.

The study is not randomized or blinded, meaning all participants and study staff know which treatment is being given. Group assignment is based on kidney function tests done during screening. The results will help researchers understand how reduced kidney function affects the way PF-07328948 works in the body.

Conditions

Renal Impairment

Healthy

Study ID

NCT07315360

Start date

Jan 28, 2026

Status verified date

May, 2026

Completion date

Mar 13, 2027

Anticipated

Primary completion date

Mar 13, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Male or female of nonchildbearing potential, between the ages of 18 and 80 years, at the screening visit.
  • BMI of 17.5 to 40.0 kg/m2 (inclusive), and a total body weight ≥45 kg (99 lbs).
  • Stable renal function, defined as ≤25% difference between 2 measurements of eGFR.
  • Group 1 only: at screening, no clinically relevant abnormalities identified by a detailed medical history, physical exam, including blood pressure and pulse rate measurement, ECG and clinical laboratory tests.
  • Group 1 only: normal renal function (mean eGFR ≥90 mL/min) based on an average of measures from the screening visits.
  • Groups 2 \& 3 only: good general health considered acceptable with the expected health status of individuals with chronic renal impairment.
  • Groups 2 \& 3 only: chronic renal impairment, defined by the following mean eGFR criteria (based on screening visits):

  • Severe RI: 15 ≤ mean eGFR <30 mL/min, not requiring hemodialysis.
  • Moderate RI: 30 ≤ mean eGFR <60 mL/min.

Exclusion Criteria:

  • Any condition possibly affecting drug absorption.
  • At screening, a positive result for HIV antibodies.
  • History of renal, liver, or heart transplantation.
  • Urinary incontinence without catheterization.
  • Evidence of a prothrombotic state, including history of deep vein thrombosis, pulmonary embolism, or arterial thrombosis, or known genetic predisposition.
  • Use of an investigational product within 30 days or 5 half-lives (whichever longer).
  • A positive urine drug test or breath alcohol test at screening or admission to study clinic.
  • Group 1 only: evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
  • Group 1 only: screening ECG demonstrating QTcF interval >450 ms or a QRS interval >120 ms.
  • Group 1 only: screening seated systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg
  • Group 2 \& 3 only: presence of acute renal disease
  • Group 2 \& 3 only: requiring dialysis or anticipated need for dialysis
  • Group 2 \& 3 only: listed for solid organ transplantation
  • Groups 2 \& 3 only: persistent severe, uncontrolled hypertension at screening, admission to study clinic, or pre-dose on Day 1.
  • Groups 2 \& 3 only: screening ECG demonstrating a QTcF interval >470 ms or a QRS interval >120 ms.
  • Groups 2 \& 3 only: unstable medical conditions or comorbidities that would interfere with study participation

Study Design

Enrollment

28 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Group 1: PF-07328948 participants without renal impairment

Participants without renal impairment will receive a single dose of PF-07328948, administered orally as 1 PF-07328948 tablet.

experimental: Group 2: PF-07328948 participants with severe renal impairment

Participants with severe renal impairment will receive a single dose of PF-07328948, administered orally as 1 PF-07328948 tablet.

experimental: Group 3: PF-07328948 participants with moderate renal impairment

Participants with moderate renal impairment will receive a single dose of PF-07328948, administered orally as 1 PF-07328948 tablet.

Interventions

PF-07328948

PF-07328948 , 1 tablet orally, once on Day 1

Primary outcome measure

  • Fraction of Unbound Drug in Plasma (Fu) of PF-07328948 [ Time Frame: At 0 (prior to dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose on Day 1 ]
  • Unbound AUCinf (AUCinf,u) of PF-07328948 [ Time Frame: At 0 (prior to dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose on Day 1 ]
  • Unbound Cmax (Cmax,u) of PF-07328948 [ Time Frame: At 0 (prior to dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose on Day 1 ]

Central Contacts and Locations

Central contacts

Pfizer CT.gov Call Center

1-800-718-1021ClinicalTrials.gov_Inquiries@pfizer.com

Locations

Orange County Research Center

Recruiting

Lake Forest, California, United States, 92630

Orlando Clinical Research Center

Recruiting

Orlando, Florida, United States, 32809

Genesis Clinical Research, LLC

Recruiting

Tampa, Florida, United States, 33603

Nucleus Network

Recruiting

Saint Paul, Minnesota, United States, 55114

More Information

Sponsor

Pfizer

Last update posted

May 12, 2026

Last verified

May, 2026

Keywords

  • Healthy Volunteers
  • Renal Impairment

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Pfizer on 2026-05-12.